Show simple item record

Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

dc.contributor.authorOudard, Stephane
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorAlva, Ajjai Shivaram
dc.contributor.authorCsoszi, Tibor
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorGeczi, Lajos
dc.contributor.authorCheng, Susanna Y.
dc.contributor.authorFradet, Yves
dc.contributor.authorVulsteke, Christof
dc.contributor.authorMorales-Barrera, Rafael
dc.contributor.authorFlechon, Aude
dc.contributor.authorGunduz, Seyda
dc.contributor.authorLoriot, Yohann
dc.contributor.authorRodriguez-Vida, Alejo
dc.contributor.authorMamtani, Ronac
dc.contributor.authorYu, Evan Y.
dc.contributor.authorNam, Kijoeng
dc.contributor.authorImai, Kentaro
dc.contributor.authorMoreno, Blanca Homet
dc.contributor.authorPowles, Thomas
dc.date.accessioned2021-12-10T12:01:44Z
dc.date.available2021-12-10T12:01:44Z
dc.date.issued2021
dc.identifier.citationÖZGÜROĞLU M., Alva A. S. , Csoszi T., Matsubara N., Geczi L., Cheng S. Y. , Fradet Y., Oudard S., Vulsteke C., Morales-Barrera R., et al., "Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.6, 2021
dc.identifier.issn0732-183X
dc.identifier.otherav_a3f1a669-43a5-4976-bca9-5f6dbb1e5545
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/173099
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.6_suppl.448
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleAnalysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentİstanbul Üniversitesi-Cerrahpaşa , Cerrahpaşa Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume39
dc.identifier.issue6
dc.contributor.firstauthorID2615943


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record